2021년 09월 24일 금요일
뉴스홈 국제
Sinovac to trial COVID-19 vaccine in South African children as part of global study

[서울=아시아뉴스통신] 레악카나기자 송고시간 2021-09-11 02:25

China's Sinovac COVID-19 vaccines produced by VACSERA Co. are seen in Cairo, Egypt July 8, 2021. (Photo by= Reuters/Shokry Hussien)

[Asia News = Reporter Reakkana] JOHANNESBURG: China's Sinovac Biotech will trial its COVID-19 vaccine in children and adolescents in South Africa as part of a global Phase III study, Sinovac and local partner Numolux Group said on Thursday (Sep 9), Reuters reported. The study will evaluate the efficacy, immunogenicity and safety of the CoronaVac vaccine on children and adolescents aged 6 months to 17 years, the firms said in a statement.
                                             
   The global trial will enrol 14,000 participants across Chile, the Philippines, Malaysia and Kenya, including 2,000 in South Africa, they said. The trial has been approved by South African drugs regulator SAHPRA, and the first child will be vaccinated at the MeCRU Clinical Research Unit based at the Sefako Makgatho Health Sciences University on Friday.
                                            
    "The primary objective of the study is to evaluate the efficacy of two doses of CoronaVac against confirmed symptomatic COVID-19 cases in children and adolescents ... efficacy will also be evaluated against hospitalisation and severe COVID-19," Sinovac and Numolux said. The South African government has said it is considering using the CoronaVac vaccine in its immunisation programme alongside shots developed by Pfizer and Johnson & Johnson which have been administered so far. 


 

[ 저작권자 © 아시아뉴스통신. 무단 전재 및 재배포금지]



제보전화 : 1644-3331    이기자의 다른뉴스보기
의견쓰기

댓글 작성을 위해 회원가입이 필요합니다.
회원가입 시 주민번호를 요구하지 않습니다.